SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second…Read More
SAB Biotherapeutics Inc SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
